Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Total Non-Current Liabilities (2023 - 2024)

Contineum Therapeutics (CTNM) has 2 years of Total Non-Current Liabilities data on record, last reported at $14.8 million in Q4 2024.

  • For Q4 2024, Total Non-Current Liabilities rose 164.32% year-over-year to $14.8 million; the TTM value through Dec 2024 reached $14.8 million, up 164.32%, while the annual FY2024 figure was $14.8 million, 164.32% up from the prior year.
  • Total Non-Current Liabilities reached $14.8 million in Q4 2024 per CTNM's latest filing, up from $5.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $14.8 million in Q4 2024 and bottomed at $3.9 million in Q2 2024.